A resolution designating February 28, 2026, as "Rare Disease Day".
- Bill Number
- S.Res. 620
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 2
- Policy Area
- Health
- Status
- Passed Senate
- Latest Action
- 2026-02-26: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
- Last Updated
- 2026-03-03T15:47:30Z
AI-Generated Summary
Purpose
This Senate resolution (S. Res. 620) aims to designate February 28, 2026, as "Rare Disease Day" in the United States. It highlights the challenges faced by individuals with rare diseases—defined as conditions affecting fewer than 200,000 people in the U.S.—and emphasizes the need for greater awareness, better diagnosis, and increased research to develop treatments and cures.
Key Provisions
- Designation of the Day: Officially recognizes February 28, 2026, as "Rare Disease Day," noting that this event has been observed annually on the last day of February since 2009, starting as a global initiative.
- Recognition of Challenges: Acknowledges that over 30 million Americans live with more than 10,000 known rare diseases, many of which are serious, life-threatening, and disproportionately affect children. It points out difficulties in diagnosis, access to expert care, and affording treatments, with about 95% of rare diseases lacking FDA-approved therapies.
- Support for Research and Programs: Commends ongoing efforts, including the 43rd anniversary of the Orphan Drug Act (a 1983 law that incentivizes drug development for rare diseases), NIH-funded research, and FDA programs like the Accelerating Rare Disease Cures initiative. It also notes that 23 of 46 new drugs approved by the FDA's Center for Drug Evaluation and Research in 2025 were for rare diseases and received orphan-drug status (a designation that provides incentives for developing treatments for rare conditions).
- Calls to Action: Urges improvements in awareness, early and accurate diagnosis, and national/global research to advance treatments, diagnostics, and cures.
Significant Changes to Existing Law
This is a non-binding resolution, so it introduces no changes to existing laws or statutes. It serves as a symbolic gesture rather than enforceable legislation, building on prior laws like the Orphan Drug Act without altering them.
Potential Impacts
- On Citizens: May increase public awareness of rare diseases, potentially leading to earlier diagnoses and better support for the estimated 30 million affected individuals and their families, though it does not provide direct funding or policy mandates.
- On Government Agencies: Encourages continued involvement from agencies like the National Institutes of Health (NIH) and Food and Drug Administration (FDA) in rare disease research and innovation, but imposes no new requirements or budgets.
- On International Relations: Reinforces U.S. participation in the global Rare Disease Day event, potentially fostering international collaboration on research without direct diplomatic effects.
Main Stakeholders Affected
- Patients and Families: Over 30 million Americans with rare diseases, including many children, who may benefit from heightened awareness and research momentum.
- Healthcare Providers: Doctors and treatment centers specializing in rare conditions, facing challenges in diagnosis and expertise.
- Researchers and Pharmaceutical Companies: Supported through recognition of NIH and FDA efforts, and incentives like orphan-drug designations.
- Government Entities: NIH and FDA, highlighted for their roles in advancing treatments.
Notable Legal, Constitutional, or Political Implications
- Legal/Constitutional: As a simple resolution agreed to by the Senate, it has no legal force and does not require presidential approval or House concurrence. It aligns with Congress's power to recognize awareness days under Article I but creates no enforceable rights or obligations.
- Political: Demonstrates bipartisan support (introduced by Senators Barrasso, a Republican, and Blumenthal, a Democrat), signaling congressional commitment to rare disease issues without controversy. It may encourage future legislative action on related topics, such as expanded funding, but remains purely symbolic.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (5)
Sen. Blumenthal, Richard [D-CT], Sen. Marshall, Roger [R-KS], Sen. Klobuchar, Amy [D-MN], Sen. Scott, Tim [R-SC], Sen. Booker, Cory A. [D-NJ]
Recent Actions
- 2026-02-26: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
- 2026-02-26: Passed/agreed to in Senate: Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
Bill Versions
- Designating February 28, 2026, as Rare Disease Day. — issued 2026-02-26 — PDF (3 pages)